Editorial: FDA should further restrict industry influence

03/23/2007 | NYTimes.com

New FDA rules that limit participation on advisory panels for medical experts with significant financial ties to industry are "encouraging," but may need to be strengthened further, The New York Times said in an editorial. Congress also should reduce reliance on user fees to lessen industry influence on the FDA, the newspaper said.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ